Stock Recommendations Today: CarTrade Tech, Dr. Reddy's Labs, Doms Industries On Brokerages' Radar
Here are the analyst calls to watch out for on Wednesday.
.jpg?auto=format%2Ccompress&fmt=avif&mode=crop&ar=16%3A9&q=60)
B&K Securities is bullish on CarTrade Tech Ltd., and holds that the company is a classic non-linear business with growth longevity.
Nuvama retained its 'buy' call on Doms Industries Ltd., and upgraded its rating on Dr. Reddy's Labs, saying its cost optimisation and backward integration are set to yield superior margins.
NDTV Profit tracks what brokerages are saying about various stocks and sectors. Here are the analyst calls to watch out for on Wednesday:
B&K Securities On CarTrade Tech
Initiated 'buy' call with a target price of Rs 1,878 apiece, indicating a potential upside of 20%.
It's a classic non-linear business with growth longevity, the brokerage said.
SAMIL is positioned to benefit during economic downturns.
OLX India being a cash cow which can deliver exponential value.
The business to reinvest cash effectively for sustained growth.
Values company at 40 times the price-to-earnings value for fiscal 2027.
Nuvama On Dr. Reddy's Laboratories
Upgraded to 'buy' from 'reduce' with a target price of Rs 1,553 per share, implying a potential upside of 14.8%.
Management has mapped out strategies to mitigate the impact of Revlimid loss.
Revlimid contributed nearly 40% to its fiscal 2024 Ebitda.
R&D spend would decrease in fiscal 2027, would soften impact on Ebitda from Revlimid expiry.
Key asset launches to fully offset revenue impact and 80% Ebitda losses from the Revlimid patent expiry.
Raised fiscal 2027 earnings by 15%, values stock at 24 times the EPS of fiscal 2027.
Nuvama On Doms Industries
Retained 'buy' with a target price of Rs 3,210 from Rs 3,237 per share, implying a potential upside of 15%.
Company's consolidated revenue to grow 23–25% in fiscal 2025.
Management believes Uniclan's growth would contribute to the goal of doubling revenue every three years.
Ebitda margin likely to be 17–17.5% in FY25.
Cost optimisation, backward integration to yield superior margins.
Cut fiscal 2025, 2026, and 2027 EPS by 3%, 6%, and 7%, respectively; valuation rollover to third quarter of fiscal 2027 at an unchanged PE of 60 times.
